secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001213900-23-033020
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar regains full rights to REZPEG from Lilly; plans Phase 2b in atopic dermatitis in 2023
--------------------------------------------------------------------------------

- Lilly terminated license agreement at will; termination effective July 22, 2023; Nektar gets all rights back.
- Nektar plans to initiate a Phase 2b study in moderate-to-severe atopic dermatitis in 2023 and explore other auto-immune indications.
- Phase 1b data showed dose-dependent improvement over placebo in EASI, EASI-75, vIGA-AD, and Itch NRS with durable response.
- Termination does not impact Nektar's cash guidance as milestone payments were not included in forecasts.
- CEO Howard Robin expresses confidence in REZPEG's potential as a remittive therapy for atopic dermatitis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390023033020/0001213900-23-033020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390023033020/ea177525-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-033020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer